• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses.

作者信息

Marin David, Goldman John M, Olavarria Eduardo, Apperley Jane F

出版信息

Blood. 2003 Oct 1;102(7):2702-3; author reply 2703-4. doi: 10.1182/blood-2003-06-2042.

DOI:10.1182/blood-2003-06-2042
PMID:14504074
Abstract
摘要

相似文献

1
Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses.对于接受常规剂量伊马替尼治疗但未实现完全细胞遗传学缓解的慢性粒细胞白血病患者，仅增加伊马替尼剂量可带来短暂获益。
Blood. 2003 Oct 1;102(7):2702-3; author reply 2703-4. doi: 10.1182/blood-2003-06-2042.
2
Sustained complete cytogenetic remission in a patient with chronic myeloid leukemia after discontinuation of imatinib mesylate therapy.
Int J Hematol. 2007 Feb;85(2):173-4. doi: 10.1532/IJH97.06187.
3
Dose modification of imatinib by monitoring the level of BCR-ABL transcript in chronic myelogenous leukemia.通过监测慢性粒细胞白血病中BCR-ABL转录本水平来调整伊马替尼剂量。
Tohoku J Exp Med. 2006 Dec;210(4):355-63. doi: 10.1620/tjem.210.355.
4
Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia.甲磺酸伊马替尼剂量递增可克服慢性粒细胞白血病患者对标准剂量治疗的耐药性。
Blood. 2003 Jan 15;101(2):473-5. doi: 10.1182/blood-2002-05-1451. Epub 2002 Sep 12.
5
Successful treatment with imatinib mesylate in a case of minor BCR-ABL-positive acute myelogenous leukemia.
Int J Hematol. 2005 Apr;81(3):242-5. doi: 10.1532/IJH97.04098.
6
Therapeutic drug monitoring in CML patients on imatinib.伊马替尼治疗的慢性粒细胞白血病患者的治疗药物监测
Blood. 2007 Sep 1;110(5):1699-701; author reply 1701. doi: 10.1182/blood-2007-03-079871.
7
Varying response to escalating the dose of imatinib in patients with CML who "acquire" a BCR-ABL M244V mutant allele.慢性粒细胞白血病（CML）患者“获得”BCR-ABL M244V突变等位基因后对伊马替尼剂量递增的反应各异。
Blood. 2006 Oct 15;108(8):2881-2. doi: 10.1182/blood-2006-05-020859.
8
Selective effect of imatinib on serum IgM in a patient with CML.
Int J Hematol. 2004 Nov;80(4):381-2. doi: 10.1532/ijh97.04105.
9
Efficacy of dose escalation of imatinib mesylate in patients with cytogenetic or hematologic resistance.甲磺酸伊马替尼剂量递增对细胞遗传学或血液学耐药患者的疗效。
Leuk Lymphoma. 2007 Aug;48(8):1659-61. doi: 10.1080/10428190701474381.
10
Chronic myeloid leukemia: where do we go now?慢性髓性白血病：我们现在何去何从？
Clin Lymphoma Myeloma. 2009;9 Suppl 4:S374-5. doi: 10.3816/CLM.2009.s.036.

引用本文的文献

1
Which Second-Line Tyrosine Kinase Inhibitor(s) for Chronic Myeloid Leukemia?哪种二线酪氨酸激酶抑制剂（s）适用于慢性髓性白血病？
Curr Treat Options Oncol. 2023 Jul;24(7):757-769. doi: 10.1007/s11864-023-01088-x. Epub 2023 Apr 29.
2
Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY.酪氨酸激酶抑制剂在常规临床实践中对慢性期慢性髓性白血病患者的中断、停药和换药：SIMPLICITY。
Am J Hematol. 2019 Jan;94(1):46-54. doi: 10.1002/ajh.25306. Epub 2018 Oct 31.
3
Management options for refractory chronic myeloid leukemia: considerations for the elderly.
难治性慢性髓性白血病的治疗选择：老年患者的考虑因素。
Drugs Aging. 2013 Jul;30(7):467-77. doi: 10.1007/s40266-013-0085-9.
4
Importance of monitoring and early switch to second generation tyrosine kinase inhibitors for the prognosis of patients with chronic myeloid leukemia with imatinib resistance or intolerance.监测及早期换用第二代酪氨酸激酶抑制剂对伊马替尼耐药或不耐受的慢性髓性白血病患者预后的重要性。
Rev Bras Hematol Hemoter. 2011;33(1):65-72. doi: 10.5581/1516-8484.20110017.
5
Gene expression signatures associated with the in vitro resistance to two tyrosine kinase inhibitors, nilotinib and imatinib.与两种酪氨酸激酶抑制剂（尼洛替尼和伊马替尼）体外耐药相关的基因表达谱。
Blood Cancer J. 2011 Aug;1(8):e32. doi: 10.1038/bcj.2011.32. Epub 2011 Aug 26.
6
NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia.NCCN 工作组报告：酪氨酸激酶抑制剂治疗在慢性髓性白血病患者管理中的选择。
J Natl Compr Canc Netw. 2011 Feb;9 Suppl 2(0 2):S1-25. doi: 10.6004/jnccn.2011.0125.
7
Patan hospital experience in treating philadelphia chromosome/BCR-ABL1 positive chronic myeloid leukemia patients with gleevec (imatinib mesylate); the first generation specific tyrosine kinase inhibitor.帕坦医院使用格列卫（甲磺酸伊马替尼）治疗费城染色体/BCR-ABL1阳性慢性髓性白血病患者的经验；第一代特异性酪氨酸激酶抑制剂。
BMC Blood Disord. 2010 Dec 7;10:8. doi: 10.1186/1471-2326-10-8.
8
Refining targeted therapies in chronic myeloid leukemia: development and application of nilotinib, a step beyond imatinib.慢性髓性白血病中靶向治疗的优化：尼洛替尼的研发与应用，超越伊马替尼的一步
Onco Targets Ther. 2008 Oct 1;1:49-58. doi: 10.2147/ott.s3291.
9
Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors.二线治疗慢性髓性白血病的长期结局：酪氨酸激酶抑制剂的综述。
Cancer. 2011 Mar 1;117(5):897-906. doi: 10.1002/cncr.25656. Epub 2010 Oct 13.
10
Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinib.对于不能耐受或对伊马替尼耐药的慢性髓性白血病患者的治疗选择。
Clin Ther. 2010 May;32(5):804-20. doi: 10.1016/j.clinthera.2010.05.003.